Proven long-term efficacy in patients with long-standing RA and inadequate response to DMARD therapy1-4

HUMIRA + MTX demonstrated clinical response in long-term, open-label studies1-3

Chart depicting “Long-Term ACR Response Rates in Open-Label Extension Studies”

The above analysis is as observed at the indicated time points. Patients with missing data were excluded.

HUMIRA + MTX demonstrated improved clinical response at 6 months in 2 controlled clinical trials of patients with long-standing RA who had inadequate response to DMARD therapy2,4,5

Chart depicting “Improved clinical responses at 6 months”

In each trial, significantly more HUMIRA + MTX patients achieved ACR20, 50, and 70 at Week 24 than patients using placebo + MTX4,5

06G-64C-Q352-6

HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older. HUMIRA can be used alone or in combination with methotrexate. HUMIRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in adult patients with psoriatic arthritis. HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Please see Important Safety Information. Serious and sometimes fatal side effects have been reported with HUMIRA, including tuberculosis and other serious infections.

Please see full prescribing information.

References: 1. Schiff MH, Breedveld FC, Weisman MH, et al. Adalimumab (HUMIRA^®) plus methotrexate is safe and efficacious in patients with rheumatoid arthritis into the 7th year of therapy. Presented at: European League Against Rheumatism Annual Scientific Meeting; June 2005; Vienna, Austria. 2. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA Trial. Arthritis Rheum. 2003;48:35-45. 3. Keystone E, Kavanaugh A, Sharp J, et al. Inhibition of radiographic disease progression in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (HUMIRA^®) plus methotrexate. Presented at: European League Against Rheumatism Annual Scientific Meeting; June 2005; Vienna, Austria. 4. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-1411. 5. HUMIRA full prescribing information.

Legal Notices/Privacy Policy. Copyright 2007, Abbott Laboratories, Abbott Park, Illinois, U.S.A. If you have any questions about Abbott's HUMIRA.com Web site that have not been answered click here. This Web site and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.